TScan Therapeutics annual operating margin
2020
2021
2022
2023
2024
2025
TScan Therapeutics Operating Margin Growth & History (TCRX)
TScan Therapeutics's operating margin was −1,315.38% for fiscal 2025.
View full TScan Therapeutics company overviewTScan Therapeutics annual operating margin history
| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −1,315.38% | +3472.30 pp |
| 2024 | 2024-12-31 | −4,787.68% | −4343.68 pp |
| 2023 | 2023-12-31 | −444.00% | +48.32 pp |
| 2022 | 2022-12-31 | −492.32% | −12.68 pp |
| 2021 | 2021-12-31 | −479.65% | +1938.14 pp |
| 2020 | 2020-12-31 | −2,417.79% | — |
TScan Therapeutics quarterly operating margin
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −2,901.33% | −1644.73 pp |
| Q1 2026 | 2026-03-31 | −2,967.31% | −1297.57 pp |
| Q4 2025 | 2025-12-31 | −929.41% | +4591.19 pp |
| Q3 2025 | 2025-09-30 | −1,475.59% | +1634.23 pp |
| Q2 2025 | 2025-06-30 | −1,256.60% | +5107.95 pp |
| Q1 2025 | 2025-03-31 | −1,669.74% | +3873.20 pp |
| Q4 2024 | 2024-12-31 | −5,520.60% | −5224.43 pp |
| Q3 2024 | 2024-09-30 | −3,109.82% | −2473.13 pp |
| Q2 2024 | 2024-06-30 | −6,364.55% | −5582.79 pp |
| Q1 2024 | 2024-03-31 | −5,542.93% | −5208.62 pp |
| Q4 2023 | 2023-12-31 | −296.17% | +306.38 pp |
| Q3 2023 | 2023-09-30 | −636.69% | −143.73 pp |
| Q2 2023 | 2023-06-30 | −781.77% | −405.88 pp |
| Q1 2023 | 2023-03-31 | −334.31% | +200.71 pp |
| Q4 2022 | 2022-12-31 | −602.55% | −104.94 pp |
| Q3 2022 | 2022-09-30 | −492.95% | +163.85 pp |
| Q2 2022 | 2022-06-30 | −375.89% | −0.92 pp |
| Q1 2022 | 2022-03-31 | −535.02% | −144.39 pp |
| Q4 2021 | 2021-12-31 | −497.62% | +1975.14 pp |
| Q3 2021 | 2021-09-30 | −656.80% | — |
| Q2 2021 | 2021-06-30 | −374.96% | — |
| Q1 2021 | 2021-03-31 | −390.63% | — |
| Q3 2020 | 2020-09-30 | −2,472.76% | — |
TScan Therapeutics operating margin trends
Over the last five reported fiscal years, TScan Therapeutics's operating margin increased from −2,417.79% to −1,315.38%, a change of +1102.41 percentage points. The latest reported quarter, Q2 2026, shows −2,901.33%.
About the metric
What operating margin means
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
Calculation and source
How operating margin is calculated
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review TScan Therapeutics filings at SEC.gov ↗